Treatment options for autoimmune cytopenias

Transfusion Medicine and Hemotherapy

Volumn 31, Issue 5, 2004, Pages 332-340

  Robak, T ^a   Robak, P ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Autoimmune hemolytic anemia; Autoimmune neutropenia; Immune thrombocytopenic purpura; Monoclonal antibodies; Rituximab

Indexed keywords

ALEMTUZUMAB; ALKYLATING AGENT; ALPHA INTERFERON; ANTIINFECTIVE AGENT; AZATHIOPRINE; CHLORAMBUCIL; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DANAZOL; DEXAMETHASONE; GLUCOCORTICOID; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY IDEC 131; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RITUXIMAB; STEROID; UNCLASSIFIED DRUG; VINCA ALKALOID; VINCRISTINE;

ANEMIA; AUTOIMMUNE CYTOPENIA; AUTOIMMUNE DISEASE; AUTOIMMUNE HEMOLYTIC ANEMIA; B LYMPHOCYTE; CELL FUNCTION; CELL TRANSPLANTATION; CLINICAL TRIAL; CYTOPENIA; DRUG RESPONSE; DRUG TARGETING; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOSUPPRESSIVE TREATMENT; NEUTROPENIA; RELAPSE; REMISSION; REVIEW; SIDE EFFECT; SPLEEN; SPLENECTOMY; STEM CELL TRANSPLANTATION; STEROID THERAPY; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 5644247341     PISSN: 16603796     EISSN: None     Source Type: Journal    
DOI: 10.1159/000081192     Document Type: Review

References (81)

1. Marsh JC, Gordon-Smith EC: CAMPATH-1H in the treatment of autoimmune cytopenias. Cytotherapy 2001;3:189-195.
2. Aster RH, George JN, McMillan R, Ganguly P: Workshop on autoimmune (idiopathic) thrombocytopenic purpura: Pathogenesis and new approaches to therapy. Am J Haematol 1998;58:231-234.
3. Shanafelt TD, Madueme HL, Wolf RC, Tefferi A: Rituximab for immune cytopenia in adults: Idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia and Evans syndrome. Mayo Clin Proc 2003;78:1340-1346.
4. Silverman GJ, Weisman S: Rituximab therapy and autoimmune disorders. Prospects for anti-B cell therapy. Arthritis Rheum 2003;18:1484-1492.
5. Cines DB, Blanchette VS: Immune thrombocytopenic purpura. N Engl J Med 2002;346:995-1008.
6. Huber MR, Kumar S, Tefferi A: Treatment advances in adult immune thrombocytopenic purpura. Ann Hematol 2003;82:723-737.
7. Provan D, Newland A: Fifty years of idiopathic thrombocytopenic purpura (ITP): Management of refractory ITP in adults. Br J Haematol 2002;118:933-944.
8. Cheng Y, Wong RSM, Soo YOY, Chui CH, Lau FY, Chan NPH, Wong WS, Cheng G: Initial treatment of immune thrombocytopenic purpura with high-dose dexamethasone. N Engl J Med 2003;349:831-836.
9. British Committee for Standards in Haematology General Haematology Task Force: Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and pregnancy. Br J Haematol 2003;120:574-596.
10. George JN, Woolf SH, Raskob GE, Wasser JS, Aledor LM, Ballem PJ, Blachette VS, Bussel JB, Cines DB, Kelton JG, Lichtin AE, McMillan R, Okerbloom JA, Regan DH, Warrier I: Idiopathic thrombocytopenia purpura: A practice guideline developed by explicit methods for American Society of Hematology. Blood 1996;88:3-40.
11. Belluicci S, Charpak Y, Chastang C, Tobelem G: Low doses vs conventional doses of corticoids in immune thrombocytopenic purpura (ITP): Results of a randomized clinical trial in 160 children 223 adults. Blood 1988;71:1165-1169.
12. Pizzuto J, Ambviz R: Therapeutic experience on 934 adults with idiopathic thrombocytopenic purpura: Multicentric trial of the Cooperative Latin American Group on Hemostasis and Thrombosis. Blood 1984;64:1179-1183.
13. Vesely SK, Perdue JJ, Rizwi MA, Terell DR, George JN: Management of adult patients with persistent idiopathic thrombocytopenic purpura following splenectomy. Ann Intern Med 2004;140:112-120.
14. Schwartz J, Deber MD, Gillis S, Giunta A, Eldor A, Bussel JB: Long term follow-up after splenectomy performed for immune thrombocytopenic purpura (ITP). Am J Hematol 2003;72:94-98.
15. Duperier T, Brody F, Felsher J, Walsh M, Rozen M, Pousky J: Predictive factors for successful laparoscopic splenectomy patients with immune thrombocytopenic purpura. Arch Surg 2004;139:61-66.
16. George JN, Aster R: Thrombocytopenia due to enhanced platelet destruction by immunologic mechanisms; in Beutler G, Coller BS, Kipps TJ (eds): Williams Hematology. New York, McGraw-Hill, 1995, pp 1315-1355.
17. Triotos G, Schlinkert RT: Laparoscopic splenectomies for immune thrombocytopenic purpura. Arch Surg 1997;132:642-646.
18. Weinmann M, Becker G, Einsele H, Bamberg M: Clinical indications and biological mechanism of splenic irradiation in autoimmune diseases. Strahlenther Onkol 2001;177:105-111.
19. Caulier MT, Darloy F, Rose C, Camier G, Morel P, Bauters F, Femaux P: Splenic irradiation for autoimmune idiopathic thrombocytopenic purpura in patients with contra-indications to splenectomy. Br J Haematol 1995;91:208-211.
20. Akoglu T, Paydas S, Bayik M, Lawrence R, Firatli T: Megadose methylprednisone pulse therapy in adult idiopathic thrombocytopenic purpura. Lancet 1991;337:56.
21. Andersen JC: Response to resistant idiopathic thrombocytopenic purpura to pulsed high-dose dexamethasone therapy. N Engl J Med 1994;330:1560-1564.
22. Khouri I, Than B, Grant K: Immune thrombocytopenic purpura. N Engl J Med 2002;347:449-450.
23. Wali YA, Al-Lamki Z, Shah W, Zacharia M, Hassan A: Pulsed high-dose dexamethasone therapy in children with chronic idiopathic thrombocytopenic purpura. Pediatr Hematol Oncol 2002;19:329-335.
24. Warner M, Wasi P, Couban S, Hayward C, Warkentin T. Kelton JG: Failure of pulse high-dose dexamethasone in chronic idiopathic immune thrombocytopenia. Am J Hematol 1997;54:267-270.
25. Stasi R, Brunetti M, Pagano A, Stipa E, Masi M, Amadori S: Pulsed intravenous high dose dexamethasone in adults with chronic idiopathic thrombocytopenic purpura. Blood Cells Mol Dis 2000;99:1578-1584.
26. Schiavoto C, Ruggeri M, Rodeghiero F: Failure of repeated courses of high-dose intravenous immunoglobulin to induce stable remission in patients with chronic idiopathic thrombocytopenic purpura. Ann Hematol 1995;70:89-90.
27. Law C, Marcaccio M, Tam P, Heddle N, Kelton JG: High-dose intravenous immune globulin and the response to splenectomy in patients with idiopathic thrombocytopenic purpura. N Engl J Med 1997;336:1494-1498.
28. Scaradavon A, Woo B, Wolski BM, Cummingham-Rundles S, Ettinger LJ, Aledort LM, Bussel JB: Intravenous anti-D treatment of immune thrombocytopenic purpura: Experience in 272 patients. Blood 1997;89:2689-2700.
29. Emmilia G, Morselli M, Luppi M, Longo G, Marasca R, Gandini G, Ferrara L, D'Apollo N, Potenza L, Bertesi M, Torelli G: Long-term salvage therapy with cyclosporin A in refractory idiopathic thrombocytopenia purpura. Blood 2002;99:1482-1485.
30. Kappers-Klumne MC, van't Veer MB: Cyclosporin A for the treatment of patients with chronic idiopathic thrombocytopenic purpura refractory to corticosteroids or splenectomy. Br J Haematol 2001;114:121-125.
31. Hou M, Peng J, Shu Y, Zhang C, Qin D, Zhav C, Ji X, Wang X, Zhang M: Mycophenolate mofetil (MMF) for the treatment of steroid resistant idiopathic thrombocytopenic purpura. Eur J Haematol 2003;70:353-357.
32. Allison AC: Immunosuppressive drugs: The first 50 years and a glance forward. Immunopharmacology 2000;47:63-83.
33. Robak T: Monoclonal antibodies in the treatment of autoimmune cytopenias. Eur J Haematol 2004;72:79-88.
34. Stasi R, Pagano A, Stipa E, Amadori S: Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic thrombocytopenic purpura. Blood 2001;98:952-957.
35. Saleh MN, Gutheil J, Moore M., Bunch PW, Butler J, Kunkel J, Grillo-Lopez AJ, LoBuglio AF: A pilot study of the anti-CD20 monoclonal antibody rituximab in patients with refractory immune thrombocytopenia. Semin Oncol 2000;27(suppl 12):99-103.
36. Zaja F, Vianelli N, Sperotto A, De Vita S, Iacona I, Zaccaria A, Masolini P, Tomadini M, Molinari AL, Bacodrani M, Fnin R: B-cell compartment as the selective target for the treatment of immune thrombocytopenias. Haematologica 2003;88:538-546.
37. Lim SH, Hale G, Marcus RE, Waldmann H, Baglin TP: CAMPATH-1 monoclonal antibody therapy in severe refractory autoimmune thrombocytopenic purpura. Br J Haematol 193;84:542-544.
38. Willis F, Marsh JC, Bevan DH, Killick JB, Lucas G, Griffiths R, Ouwehando W, Hale G, Waldmann H, Gordon-Smith EC: The effect of treatment with Campath 1-H in patients with autoimmune cytopenias. Br J Haematol 2001;114:891-898.
39. Robak T: Monoclonal antibodies in the treatment of chronic lymphoid leukemias. Leuk Lymphoma 2004;45:208-218.
40. Kuwana M, Nomura S, Fujimura T, Muto Y, Kurata Y, Tanaka S, Ikeda Y: Effect of a single injection of humanized anti-CD154 monoclonal antibody on the platelet specific autoimmune response in patients with immune thrombocytopenic purpura. Blood 2004;103:1229-1236.
41. Thomas AT: Autoimmune hemolytic anemias; in Lee GR, Foerster J, Lukens J, Paraskevas F, Greer JP, Rodgers GM (eds): Wintrobe's Clinical Haematology, 10th ed. Philadelphia, Lippincott Williams and Wilkins 1998, pp 1233-1263.
42. Engelfriet CP, Overbeeke MA, von dem Borne AE: Autoimmune hemolytic anemia. Semin Hematol 1992;29:3-12.
43. Sokol RJ, Hewitt S, Stamps BK. Autoimmune hemolysis: An 18 year study of 865 cases referred to a regional transfusion centre. Br Med J 1981;282:2023-2027.
44. Gehrs BC, Friedberg RC: Autoimmune hemolytic anemia. Am J Hematol 2002;69:258-271.
45. Markus H, Forfar JC: Splenic irradiation in treating warm autoimmune hemolytic anemia. Br Med J Clin Res Ed 1986;293:839-840.
46. Panle B, Brion N, Brion G: Remission of autoimmune hemolytic anemia associated with chronic lymphocytic leukemia following splenic irradiation. Nouv Rev Fr Hematol 1989;31:413-416.
47. Hershko C, Sonnenblick M, Ahkemazi J: Control of steroid-resistant autoimmune haemolytic anaemia by cyclosporine. Br J Haematol 1990;76:436-437.
48. Quartier P, Brethon B, Philippet P, Ladman-Parker J, Le Deist F, Fischer A: Treatment of childhood autoimmune haemolytic anemia with rituximab. Lancet 2001;358:1511-1513.
49. Ahrens N, Kingreen D, Seltsam A, Salama A: Treatment of refractory autoimmune haemolytic anaemia with anti-CD20 (rituximab). Br J Hematol 2001;114:244-245.
50. Gupta N, Kuvaru S, Patel D, Janson D, Driscoll N, Ahmed S, Rai KR: Rituximab based chemotherapy for steroid-refractory autoimmune hemolytic anemia of chronic lymphocytic leukemia. Leukemia 2002;16:2092-2095.
51. Seipelt G, Bohme A, Koschmieder S, Hoelzer D: Effective treatment with rituximab in a patient with refractory prolymphocytoid transformed B-chronic lymphocytic leukemia and Evans syndrome. Ann Hematol 2001;80:170-173.
52. Chemnitz J, Draube A, Diehl V, Wolf J: Successful treatment of steroid and cyclophosphamide-resistant chronic lymphocytic leukemia with rituximab. Ann J Hematol 2002;69:232-233.
53. Trape G, Fianchi L, Lai M, Laurenti L, Piscitelli R, Leone G, Pagano L: Rituximab chimeric anti-CD20 monoclonal antibody treatment for refractory hemolytic anemia in patients with lymphoproliferative disorders. Haematologica 2003;88:223-225.
54. Iannitto E, Ammatuna E, Marino C, Cirincione S, Greco G, Mariani G: Sustained response of refractory chronic lymphocytic leukemia in progression complicated by acute hemolytic anemia and anti-CD20 monoclonal antibody. Blood 2002;99:1096-1097.
55. Perotta S, Locatelli F, La Manna A, Cennamo L, De Stefano P, Nobili B: Anti-CD20 monoclonal antibody (rituximab) for life threatening autoimmune haemolytic anemia in a patient with systemic lupus erythematosus. Br J Haematol 2002;116:465-467.
56. Scheinberg P: Stem cell transplantation for autoimmune diseases. Cytotherapy 2003;5:243-251.
57. Seeliger S, Baumann M, Mohr M, Jurgens H, Frosch M, Vormoor J: Autologous peripheral blood stem cell transplantation and anti-B cell directed immunotherapy for refractory auto-immune haemolytic anaemia. Eur J Pediatr 2001;150:492-496.
58. Jindra P, Koza V, Vozobulova V, Svojgtova M: Autologous CD34 cell transplantation after FAMP treatment in a patient with CLL and persisting AIHA: Complete remission of lymphoma with control of autoimmune complications. Bone Marrow Transpl 1999;24:215-217.
59. De Stefano P, Zecca M, Giorgiani G, Parotti C, Giraldi E: Resolution of immune haemolytic anaemia with allogenic bone marrow transplantation after an unsuccessful autograft. Br J Haematol 1989;106:1063-1064.
60. Oyama Y, Papadogoulos EB, Miranda M, Traynor AE, Burt RK: Allogenic stem cell transplantation for Evans syndrome. Bone Marrow Transplant 2001;28:903-905.
61. Reatz E, Beatty PG, Adams RH: Treatment of severe Evans syndrome with an allogenic cord blood transplant. Bone Marrow Transplant 1997;20:427-429.
62. O'Connor B, Clifford JS, Lawrence WD, Logne GL: Alpha-interferon for severe cold agglutinin disease. Ann Intern Med 1989;112:255-266.
63. Petz LD: Treatment of autoimmune hemolytic anemias. Curr Opin Hematol 2001;8:411-416.
64. Berentsen S, Tjonnfjord GE, Brudevold R, Gjersten BT, Langholm R, Lokkevik E, Sorbo JH, Ulvestad E: Favourable response to therapy with the anti-CD20 monoclonal antibody rituximab in primary chronic cold agglutinin disease. Br J Haematol 2001;115:79-83.
65. Camou F,Vallard JF, Pellegrin JL: Rituximab in cold agglutinin disease. Rev Med Intern 2003;24:501-504.
66. Bernstein S, Ulvestad E, Gjertsen BT, Hjorth-Hansen H, Langholm R, Knutsen H, Ghanima W, Shammas FV, Tjonnfjord GE: Rituximab for primary cold agglutinin disease: A prospective study of 37 courses of therapy in 27 patients. Blood 2004;103:2925-2928.
67. Zaja F, Russo D, Fuga G, Michelutti T, Sperotto A, Fanin R, Baccarani M: Rituximab in a case of cold agglutinin disease. Br J Hematol 2001;115:230-233.
68. Lavios N, Van Den Neste E, Jost E, Deneys V, Scheiff JM, Ferrant A: Remission of severe cold agglutinin disease after rituximab therapy. Leukemia 2001;15:187-188.
69. Cohen Y, Polliack A, Zelig O, Goldfarb A: Monotherapy with rituximab induces rapid remission of recurrent cold agglutinin-mediated hemolytic anemia in a patient with indolent lymphoplasmacytic lymphoma. Leuk Lymphoma 2001;42:1405-1408.
70. Mori A, Tamaru J, Sumi H, Kondo H: Beneficial effects of rituximab on primary cold agglutinin disease refractory to conventional therapy. Eur J Haematol 2002;68:243-246.
71. Bauduer F: Rituximab: A very efficient therapy in cold agglutinins and refractory autoimmune haemolytic anaemia associated with CD20 positive, low-grade non Hodgkin's lymphoma. Br J Haematol 2001;112:1085-1086.
72. Morselli M, Luppi M, Potenza L, Facchini L, Tonelli S, Dini D, Leonardi G, Donelli A, Narni F, Torelli G: Mixed warm and cold autoimmune hemolytic anemia: Complete recovery after 2 courses of rituximab treatment. Blood 2002;99:3478-3479.
73. Zaja F, Russo D, Fuga G, Patriarca F, Ermacora A, Baccarani M: Rituximab for the treatment of type II mixed cryoglobulinemia. Haematologica 1999;84:1157-1158.
74. Palmblad J, Papadaki HA, Eliopoulos G: Acute and chronic neutropenias. What is new? J Intern Med 2001;250:476-491.
75. Smith MA, Smith JG: The use of granulocyte colony-stimulating factor for treatment of autoimmune neutropenia. Curr Opin Hematol 2001;8:165-169.
76. Lyall EG, Lucas GF, Eden OB: Autoimmune neutropenia of infancy. J Clin Pathol 1997;45:431-434.
77. Bux J, Champman J: Report on the Second International Granulocyte Serology Workshop. Transfusion 1997;37:977-983.
78. Watts RG: Neutropenia; in Lee GR, Foerster J, Lukens J, Paraskevas F, Greer JP, Rodgers GM (eds): Wintrobe's Clinical Hematology, 10th ed. Philadelphia, Lippincott Williams and Wilkins 1998, pp 1862-1888.
79. Killick SB, Marsh JCW, Hale G, Waldmann H, Kelly SJ, Gordon-Smith EC: Sustained remission of severe resistant autoimmune neutropenia with Campath 1H. Br J Haematol 1997;97:306-308.
80. Takahashi K, Taniguchi S, Akashi K: Human recombinant granulocyte colony stimulating factor for the treatment of autoimmune neutropenia. Acta Hematol 1991;86:95-98.
81. Bauder F: G-CSF: A very efficient therapy in chronic autoimmune neutropenia. A brief review of the literature. Hematol Cell Ther 1998;40:189-191.